CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(04): 370-375
DOI: 10.1055/s-0041-1731861
How I Treat

How We Treat HER2-Positive Metastatic Breast Cancer

Ashok S. Komaranchath
1   Department of Oncology, Aster Medcity, Kochi, Kerala, India
,
Aju Mathew
2   Department of Oncology, MOSC Medical College, Kolenchery, Kerala, India
3   Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
› Institutsangaben

Introduction

Overexpression of the human epidermal growth factor receptor-2 (HER2), or amplification of the HER2 gene, is seen in approximately 15 to 25% of all breast cancer patients.[1] Real-world data from hospital-based cohorts estimated a prevalence of 23%.[2] Far more patients in India present with advanced disease when compared with high-income countries. In this narrative review, we describe the current landscape of HER2 targeting. We focus on how we treat HER2-positive metastatic breast cancer (MBC).



Publikationsverlauf

Artikel online veröffentlicht:
26. November 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India